Image-Guided Minimally Invasive Spinal Decompression (IG‑MILD/PILD) — Coverage for HCPCS G0276
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and coding for percutaneous image-guided minimally invasive lumbar decompression (mild®/IG‑MILD/PILD) procedures, addressing Medicare Advantage and Commercial product coverage and specifically noting HCPCS code G0276. It affects providers submitting claims to Blue Cross Blue Shield - Rhode Island.
No material clinical or coverage changes in this revision.
Coverage Criteria
Coverage by product
Covered when ALL of the following are met:
BCBSRI follows CMS guidelines; claims for services in an approved clinical study must be billed with the appropriate study modifier (Q0 for investigational clinical service or Q1 for routine clinical service).
Product-specific coverage
Coverage stance differs by product:
Claims must be billed with appropriate modifiers (Q0 or Q1) and follow the payer's Clinical Trials Medicare Advantage Plans policy.
The procedure is considered not medically necessary for Commercial members due to insufficient evidence of improvement in net health outcome.
The devices and procedure described for percutaneous image‑guided minimally invasive spinal decompression (mild®/IG‑MILD) are intended to treat central lumbar spinal stenosis by resecting hypertrophied ligamentum flavum and small laminar bone under fluoroscopic guidance. These instruments and the procedure are not intended for disc procedures and are not intended for use near the lateral neural elements. The policy cites the device instructions and procedural description that limit use to perilaminar/interlaminar tissue resection and explicitly contraindicate disc procedures or decompression of lateral neural elements.
HCPCS G0276 is specifically identified in this policy and is stated to be not medically necessary for Commercial Products. The policy lists G0276 as the code for a blinded percutaneous image‑guided lumbar decompression (PILD) or placebo‑control procedure performed in an approved CED clinical trial and explicitly states that this service is not covered for Commercial members.
For Commercial Products the policy considers a blinded PILD or placebo‑control procedure to be not medically necessary. The rationale provided is that the evidence is insufficient to demonstrate an improvement in net health outcome for a blinded PILD or placebo‑control approach, and therefore these blinded trial procedures (HCPCS G0276) are not supported for Commercial coverage.
The policy explicitly lists the following service as not medically necessary for Commercial Products: HCPCS G0276 — "Blinded procedure for lumbar stenosis, percutaneous image‑guided lumbar decompression (PILD) or placebo‑control, performed in an approved coverage with evidence development (CED) clinical trial."
Coding and Billing Codes
| G0276 | Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial |
| Modifier Q0 | Investigational clinical service provided in a clinical research study that is in an approved research study (Medicare claims filed without the Q0 modifier will deny as not medically necessary) |
| Modifier Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study |
| G0276 | Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial |
| G0276 | Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial |
| Q0 | Modifier: Investigational clinical service provided in a clinical research study that is in an approved research study |
| Q1 | Modifier: Routine clinical service provided in a clinical research study that is in an approved clinical research study |
Provider Actions, Billing & Documentation
Prior authorization: Not applicable
Prior authorization is not required for G0276.
Step therapy / medical criteria: Not applicable
There are no step therapy requirements or medical-necessity criteria specified for this service in this policy.
Provider actions when treating Medicare Advantage members in CED studies
Follow the payer’s Clinical Trials Medicare Advantage Plans policy and CMS CED study requirements when enrolling and treating Medicare Advantage members in an approved trial.
- Ensure the member is enrolled in the CMS-approved CED clinical trial before performing G0276.
- Bill services using the appropriate clinical-trial modifiers (Q0 or Q1) as specified for Medicare Advantage.
Billing and documentation for Medicare CED
When treating a Medicare Advantage member as part of a CMS-approved study, follow procedures for correct billing and coding of services and bill with the appropriate modifier (Q0 or Q1).
- Reference the Clinical Trials Medicare Advantage Plans policy for operational billing procedures.
- Use modifier Q0 for investigational clinical services and Q1 for routine clinical services as applicable.
Documentation and billing guidance for Medicare Advantage clinical trials
Bill Medicare Advantage claims for services rendered in a CMS-approved clinical study with the required modifier: Q0 for investigational clinical services or Q1 for routine clinical services.
- Medicare claims filed without the Q0 modifier for investigational services will deny as not medically necessary.
- Ensure claims reflect the member’s participation in the approved CED trial per CMS guidance.
Denial risk if Q0 modifier omitted
Medicare claims for investigational clinical services submitted without modifier Q0 will deny as not medically necessary.
Required billing modifiers for CMS-approved clinical studies
Medicare Advantage claims for routine or investigational services rendered as part of an approved clinical study must be billed with the appropriate modifier: Q0 for investigational clinical services and Q1 for routine clinical services.
- Modifier Q0 — Investigational clinical service provided in an approved research study.
- Modifier Q1 — Routine clinical service provided in an approved clinical research study.
Commercial product denial risk for G0276
For Commercial Products, G0276 (blinded PILD or placebo-control performed in a CED trial) is not medically necessary and may be denied.
Background
Lumbar spinal stenosis (LSS) is a narrowing of the spinal canal that can cause neurogenic claudication and radicular symptoms. Conventional surgical decompression (eg, laminectomy, laminotomy) is an established treatment for symptomatic LSS. The percutaneous image‑guided minimally invasive decompression (mild®/IG‑MILD) procedure is an ultra‑minimally invasive, fluoroscopically guided technique that removes hypertrophied ligamentum flavum and small amounts of lamina to decompress the central canal without endoscopic visualization. Because the technique is limited to central canal decompression, it does not address disc herniation or lateral nerve root compression and is contraindicated for disc procedures.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.